Markets extend their rally over Pfizer’s full FDA approval - Tuesday Review, August 24

Markets extend their rally over Pfizer’s full FDA approval - Tuesday Review, August 24

German economic data showed the GDP rose more than expected in Q2

The US

Wall Street ended higher, as the FDA’s full approval of a COVID-19 vaccine and the absence of negative catalysts kept risk appetite alive ahead of the Jackson Hole Symposium. USA30 rose 0.09%, and USA500 gained 0.15%. TECH100 added 0.52%.

Crude oil went up 1.1% at $66.39 a barrel.

Gold rose 0.2% to $1,803.15 per ounce.

Asia and Australia

Stocks were up, boosted by the FDA’s approval of the COVID-19 vaccine, which is expected to increase US vaccination rates and assuage concerns over the virus’s impact on global economic recovery.

Japan225 rose 1.12%.

HongKong45 was up 0.28%.

Down under, Australia200 traded 0.28% higher.

Europe

Markets closed in the green, helped by stronger than expected German growth and the full US approval of the Pfizer-BioNTech COVID-19 vaccine.

Germany30 traded 0.2% higher. France40 and UK100 each added 0.1%.

Brent oil rose 1.2% to $69.19 per barrel.

EUR/USD lost 0.1% trading at 1.1737.

Sources: investing.com, reuters.com

This information prepared by za.capex.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of za.capex.com

JME Financial Services (Pty) Ltd trading as ZA.CAPEX.COM acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via ZA.CAPEX.COM, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15. Magnasale Trading Ltd is the principal to the CFD purchased by investors.